Phase 3 N=300 The Effect of Pretreatment With Roc on Succinylcholine Myalgias
Myalgia
Primary: Myalgias Perceived at 3 Hours — 81; 83; 83; 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
Upper Back Pain
Primary: Mean Change From Baseline of Both AM and PM Spasm Assessment Scores — 1.66; 1.87; 1.91; 1.54 Score on a Scale — p=0.68
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
Phase 2 N=45 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Phase 4 N=23 Mexiletine for the Treatment of Muscle Cramps in ALS
Muscle Cramps in Amyotrophic Lateral Sclerosis
Primary: Daily Muscle Cramps — 6.1; 4.7; 4.9; 2.5 Cramps per 24 hours
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Phase 3 N=205 Topical Ibuprofen for Delayed Onset Mulscle Soreness
Pain
Primary: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1 (MSM 0-24 ) — 22.2; 17.8; 29.7 units on a scale — p=0.200
Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001
N/A N=1,002 The Maintaining Musculoskeletal Health Study
Widespread Chronic Pain
Primary: Development of Chronic Widespread Pain Assessed by Questionnaire — 69; 77 Participants
Phase 3 N=102 A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Muscle Soreness
Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW. — 50.15; 54.83 units on a scale (NRS)
Phase 2 N=24 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Myasthenia Gravis
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) — 10; 10; 8; 3 Participants
N/A N=52 Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
Chronic Fatigue Syndrome
Primary: Cardiopulmonary Exercise Test (CPET) - ATVO2rel — 16.0; 10.6 mL/kg/min
Phase 2 N=207 Testing Mestinon and Exercise in Fibromyalgia
Fibromyalgia
Primary: Levels of Growth Hormone Post Exercise — 4.95; 1.41 ng/ml — p=<0.02
Phase 3 N=180 Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
Neck Pain · Back Pain · Spasm
Primary: Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment — 20.0; 28.9; 60.0; 46.7 percentage of participants — p=0.6179
N/A N=500 Milgamma® and Milgamma® Compositum Step-therapy in Patients With Acute Non-specific Low Back Pain Receiving Modern NSAID
Acute Non-specific Low Back Pain
Primary: Change of Pain Intensity After 10 Days of Treatment — -5.1; -4.0 units on a scale — p=<0.001
Phase 1 N=7 S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
RYR-1 Myopathy
Primary: Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210) — 0; 0; 0; 0 Participants
Phase 4 N=24 An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS
Pain · Delayed Onset Muscle Soreness
Primary: Mean Reduction in SPID Scores of DOMS on Walking Over 24 Hours — 34.87; 23.62 units on a scale — p=0.0324
Phase 3 N=39 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Pain · Weakness · Cramps
Primary: Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use — 53; 65 % of participants with pain reduction
Phase 2 N=59 Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
Phase 2 N=20 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers
Muscle Damage · Muscle Inflammation
Primary: Quadriceps Muscle Strength — 151; 160 lbs — p=>0.05
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
Phase 4 N=16 Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
Pompe Disease (Late-Onset) · Glycogen Storage Disease Type II (GSD II) · Glycogenesis 2 Acid Maltase Deficiency
Primary: Change From Baseline in Tissue Glycogen Content in Quadriceps Muscle Biopsy Samples at Week 26 — 5.3; -1.6 percent area occupied by glycogen — p=0.1860
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
N/A N=34 Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training
Sarcopenia · Osteoporosis · Aging
Primary: Change in Total Body Fat-free Mass — 1.5; 2.3; 0.7 kg — p=0.38
N/A N=66 Tai Chi Mind-Body Therapy for Fibromyalgia
Fibromyalgia
Primary: Mean Change From Baseline of Fibromyalgia Impact Questionnaire Score — -27.8; -9.4 units on a scale